Posted inGastroenterology Internal Medicine news
Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial
The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted therapy as a novel approach.